secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2022-12-23T23:59:59+00:00
Accession:  0001193125-22-311537
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal raises $259M in equity and $50M debt capacity; NDA submission planned H1 2023
--------------------------------------------------------------------------------

- $159M in gross ATM common stock sales and $100M registered direct offering (Series B preferred and common) completed.
- Hercules Capital confirms clinical milestone, enabling $50M additional draw under existing credit facility.
- Net proceeds ~$305.4M to fund resmetirom development and potential U.S. launch.
- Company intends to submit new drug application for resmetirom in first half of 2023.
- Series B preferred convertible at $225/share, substantially similar to existing Series A; closing expected Dec 23, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312522311537/0001193125-22-311537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312522311537/d434336d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer